RegCell, Inc.
- Biotech or pharma, therapeutic R&D
RegCell has developed a novel epigenetic reprogramming platform to convert pathogenic T-cells into highly functional lineage-stable regulatory T-cells capable of targeting complex and undefined pathogenic antigens with curative potential. The company was recently awarded 37M+ in non-dilutive funding, providing a capital-efficient pathway to multiple value-creating clinical milestones over the next few years. We are financed by leading institutional and corporate investors.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}